Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esaxerenone Add-on Therapy for CKD Patients with Uncontrolled Hypertension
jRCT1061230053Recruiting
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of esaxerenone in chronic kidney disease (CKD) and hypertension (HTN). Primary endpoint: Percent reduction in UPCR at 12 weeks. Started Apr 2024; status: recruiting.
02
Drugs
esaxerenone
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on jRCT1061230053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061230053.